About Adlai Nortye Ltd.
https://www.adlainortye.comAdlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
CEO
Yang Lu
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public September 29, 2023
Method of going public IPO
Full time employees 123
Most Recent Analyst Grades
Grade Summary
Neutral 1
Showing Top 1 of 1
Price Target
Target High $9
Target Low $9
Target Median $9
Target Consensus $9
Market Cap $45.92 M
52w High $2.75
52w Low $0.88
P/E -1.41
Volume 30.00K
Outstanding Shares 31.24M
About Adlai Nortye Ltd.
https://www.adlainortye.comAdlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2024 | $745K | $14.08M | $-13.81M | -1.85K% | $-1.59 | $-14.36M |
| Q1-2024 | $745K ▼ | $14.08M ▼ | $-13.81M ▼ | -1.85K% ▼ | $-1.59 ▲ | $-14.36M ▲ |
| Q4-2023 | $2.5M | $25.3M ▲ | $-13.23M | -529.06% | $-1.95 | $-17.43M |
| Q3-2023 | $2.5M ▲ | $15.13M ▼ | $-13.23M ▲ | -529.06% ▼ | $-1.95 ▲ | $-17.43M ▲ |
| Q2-2023 | $0 | $16.86M | $-63.4M | 0% | $-7.47 | $-62.59M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $44.15M ▼ | $72.05M ▲ | $64.12M ▲ | $7.92M ▼ |
| Q4-2024 | $60.91M ▼ | $71.27M ▼ | $45.78M ▼ | $25.48M ▼ |
| Q2-2024 | $97.99M | $107.68M | $54.31M | $53.37M |
| Q1-2024 | $97.99M ▼ | $107.68M ▼ | $54.31M ▲ | $53.37M ▼ |
| Q4-2023 | $98.72M | $130.19M | $50.79M | $79.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2024 | $-13.81M | $-14.19M | $13.76M | $3.75M | $3.24M | $-14.25M |
| Q1-2024 | $-13.81M ▼ | $-14.19M ▲ | $13.76M ▲ | $3.75M ▼ | $3.24M ▼ | $-14.25M ▲ |
| Q4-2023 | $-13.23M | $-19.16M | $-16.16M | $50.64M | $15.73M | $-19.22M |
| Q3-2023 | $-13.23M ▲ | $-19.16M ▼ | $-16.16M ▼ | $50.64M ▲ | $15.73M ▲ | $-19.22M ▼ |
| Q2-2023 | $-63.4M | $-8.32M | $39K | $9.47M | $189K | $-8.38M |
CEO
Yang Lu
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public September 29, 2023
Method of going public IPO
Full time employees 123
Most Recent Analyst Grades
Grade Summary
Neutral 1
Showing Top 1 of 1
Price Target
Target High $9
Target Low $9
Target Median $9
Target Consensus $9